Salute e Benessere

DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial…

DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr. Trapp will report directly to Daniel Tasse, Chief Executive Officer, as a member of the executive team and will lead all aspects of global commercial strategy and...
Nasdaq GlobeNewswire
03/11/2025

Information Regarding the Total Number of Voting Rights and Total Number of…

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025 (Article 223-16 of the General Regulations of theAutorité des Marchés Financiers )Market : NYSE Euronext ParisISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights10/31/2025 179,827,919 Total gross of voting rights: 179,827,919 Total net* of voting rights: 179,741,847 ...
Nasdaq GlobeNewswire
03/11/2025

NANOBIOTIX to Participate in Investor Conferences the Week of November 10th

PARIS and CAMBRIDGE, Mass., Nov.03, 2025(GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “ Company ”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conferences: UBS Global Healthcare ConferenceDate: Monday, November 10, 2025 Time: 5pm ET / 11pm CET...
Nasdaq GlobeNewswire
03/11/2025

Nyxoah to Participate in the Stifel 2025 Healthcare Conference

Nyxoah to Participate in the Stifel 2025 Healthcare ConferenceMont-Saint-Guibert, Belgium – November 3, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Stifel 2025 Healthcare Conference on Tuesday, Nov. 11, 2025. The Company is scheduled to present at 9:20am Eastern Time the same day via webcast...
Nasdaq GlobeNewswire
03/11/2025

Galapagos to Present New Data from Cell Therapy Program at ASH 2025

Oral presentation of GLPG5101 data from the ATALANTA-1 study in patients with high-risk relapsed/refractory mantle cell lymphomaTwo abstracts featuring new Phase 2 data highlight the potential of CAR-T cell therapy candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma Results demonstrate high rates of complete and durable responses along with low rates of high-grade toxicities using GLPG5101 manufactured on innovative median seven-day vein-to-vein time platform,...
Nasdaq GlobeNewswire
03/11/2025

CQ Medical® Appoints Michael Galbus as Chief Executive Officer, Mike Sutter as…

Michael brings more than 30 years of leadership experience across highly regulated industries, including aerospace, building products, chemicals, and medical devices. He has learned to quickly identify what makes organizations in different sectors succeed and has applied those insights to deliver performance and growth. His leadership journey has included senior roles at global companies such as Dow Inc., Saint-Gobain, Zodiac Aerospace, and ACTEGA, culminating in his appointment as CEO of CQ…
PR Newswire
03/11/2025

Oxurion ends discussions regarding previously announced preclinical transaction…

Leuven, BELGIUM, November 3, 2025, 6:00 PM – Oxurion NV (Euronext Brussels: OXUR), a pharmaceutical outsourcing company based in Leuven, announces the termination of discussions regarding the planned acquisition of a company specialized in preclinical microbiology services (see press release dated June 19, 2025 – link)…
Actusnews Wire
03/11/2025

Oxurion beëindigt gesprekken over eerder aangekondigde preklinische overname en…

Leuven, BELGIË, 3 november 2025, 18u00 – Oxurion NV (Euronext Brussel: OXUR) een farmaceutische onderaannemingsvennootschap gevestigd in Leuven, maakt bekend dat het de gesprekken heeft beëindigd met betrekking tot de overwogene overname van een vennootschap gespecialiseerd in preklinische microbiologische diensten (zie persbericht van 19 juni 2025 – link)…
Actusnews Wire
03/11/2025

Traditional Wound Care Products Market Driven by Rising Chronic Wound Cases, and…

Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=287622 Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=287622 202 - Pages 126 – Tables37 – Figures Scope Of The Report Traditional Wound Care Products Market Overview 1. Rising Prevalence of Chronic and Acute Wounds The Traditional Wound Care Products Market continues to expand due to the increasing prevalence of chronic wounds such as...
PR Newswire
03/11/2025

Zelluna ASA – Contemplates private placement

Zelluna ASA – Contemplates private placement of NOK 50-55 million and retail offering to advance into first-in-human trial of its “off-the-shelf” TCR-NK therapyNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL Oslo, 3...
Nasdaq GlobeNewswire
03/11/2025

Zelluna ASA Reports Third Quarter 2025 Financial Results and Provides General…

Oslo, Norway, 3 November 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its third quarter 2025 results today.Webcast scheduled for 4 November 2025, at 09:00 (CET). Link to webcast here . Third Quarter 2025 Business UpdateHighlights Positive MHRA feedback and strengthened clinical strategy supporting UK clinical developmentIn October 2025...
Nasdaq GlobeNewswire
03/11/2025

ECG Cable & Lead Wire Market worth $3.76 billion by 2030 with 6.8% CAGR |…

Browse in-depth TOC on "ECG Cables and Lead Wires Market"280 - Tables64 - Figures300 - Pages Browse in-depth TOC on "ECG Cables and Lead Wires Market" 280 - Tables 64 - Figures 300 - Pages By ECG lead wire type,the ECG cable & lead wire market is segmented into ECG lead wire and ECG cable. The ECG lead wire market is divided into 12-lead ECG wires, 5-lead ECG wires, 3-lead ECG wires, 6-lead ECG wires, single-lead ECG wires, and other ECG lead wires. In 2024, 12-lead…
PR Newswire
03/11/2025

Personal Care Emulsifiers Market to Reach $2.8 Billion, Globally, by 2034 at…

Rising Male Grooming Trends Rising Male Grooming Trends The rising trend in male grooming is significantly contributing to the growth of the Personal Care Emulsifiers market. The personal care industry was largely female-centric, but recent years have seen a shift in consumer behavior, with men increasingly investing in grooming and skincare routines. This trend is particularly evident in urban areas where lifestyle changes, greater awareness of personal hygiene, and the influence of...
PR Newswire
03/11/2025

Latest Real-World Clinical Data Demonstrate a 19.6 mmHg Reduction in Blood…

19.6 mmHg BP Reduction in 6-Month Data from the GPS Registry The GPS Registry is a real world, all comers, prospective and retrospective registry being conducted in nine countries outside ofthe United States, designed to assess the long-term safety and effectiveness of the Paradise uRDN system when used according to its labeling. Presented by Dr.Karl Fengler, Heart Center,Leipzig, the results included the first prospective analysis of data from 212 patients...
PR Newswire
03/11/2025

Peli BioThermal Opens Expanded Allentown, PA Service Center to Support Growing…

"To us, this new facility represents more than just additional space—it reflects Peli BioThermal's continued growth, commitment to innovation, and unwavering focus on supporting our customers," said Sam Herbert, CEO of Peli BioThermal. "We are investing in the future of cold chain logistics to ensure we deliver the flexibility, reliability, and protection our customers need for their life-saving therapies." "To us, this new facility represents more than just additional…
PR Newswire
03/11/2025

Cellectis to Present a Development Update for eti-cel at ASH 2025

Preliminary data recently shared for eti-cel (UCART20x22) show an 86% ORR and a 57% CR rate (n=7), underscoring its potential to improve outcomes in r/r NHLPreclinical data demonstrated that combining eti-cel with low-dose IL-2 may deepen and extend anti-tumor activity in patients with r/r NHLEti-cel full Phase 1 dataset, including low-dose IL-2 combination cohorts, expected to be presented in 2026Correlation between alemtuzumab exposure and response with lasme-cel...
Nasdaq GlobeNewswire
03/11/2025

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American…

Media ReleaseCOPENHAGEN, Denmark; November 3, 2025 More than 20 abstracts, including seven oral presentations, highlight advancements from the epcoritamab development program supporting the expanded clinical profile and potential of epcoritamab for a broader range of B-cell malignanciesNew data demonstrate potential of epcoritamab in first and second-line settings in follicular lymphoma (FL) and first-line in diffuse large B-cell lymphoma (DLBCL) Results from Phase 3 EPCORE...
Nasdaq GlobeNewswire
03/11/2025

Roche to present new data from its broad and innovative haematology portfolio at…

Findings further demonstrate the effectiveness of Roche’s approved medicines in advancing treatment standards for people with blood disordersData from innovative pipeline signals progress toward improved outcomes in haemophilia A, lymphoma, and multiple myeloma Basel, 3 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will showcase 46 abstracts, including 12 oral presentations, from its industry-leading haematology portfolio at the 67 thAmerican Society...
Nasdaq GlobeNewswire
03/11/2025

Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine…

Evaxion introduces EVX-04, a novel vaccine candidate targeting multiple non-conventional ERV tumor antigens, developed withour AI-Immunology™ platformEVX-04 is a therapeutic cancer vaccine candidate designed for acute myeloid leukemiaNew data showing EVX-04 induces strong T-cell responses and cancer cell killing will be presented at an oral session at the American Society of Hematology (ASH) Annual Meeting and Exposition in Florida on December 6, 2025The concept behind EVX-04...
Nasdaq GlobeNewswire
03/11/2025

AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen®…

AIM ImmunoTech Inc.(NYSE American: AIM) (“AIM” or the “Company”) today announced that the European Patent Office has officially granted AIM’s European Patent No. 4,096,675, titled “Compositions for Treating LONG COVID,” covering compositions of matter of AIM’s proprietary dsRNAs including, for example, Ampligen ® (rintatolimod) for use in the treatment of Long COVID.“While AIM’s immediate and primary focus is to build upon the continued positive results from our late-stage pancreatic...
Nasdaq GlobeNewswire
03/11/2025

Lilly plans to build a new €2.6 billion facility to boost oral medicine…

The facility will incorporate advanced manufacturing technologies to meet the needs of Lilly's growing portfolio of oral solid medicines in cardiometabolic health, neuroscience, oncology and immunology. Innovative capabilities will include dock-to-dock automation and material flow, paperless manufacturing, process analytical technology and spray-dried dispersion, which allows oral medicines to be effectively absorbed. The facility will incorporate advanced manufacturing technologies to meet...
PR Newswire
03/11/2025

Ardena strengthens executive leadership with appointments of Chief Quality…

Dipesh Patel brings more than 25 years of experience in the pharmaceutical industry, having held senior leadership roles across CDMOs, virtual biotech companies, and large-scale manufacturing organizations. With an academic background in Chemistry, Biology, and Toxicology, he has built a strong track record in both Quality and Operations, overseeing a broad range of dosage forms and regulatory frameworks. His global experience provides deep insight into diverse regulatory requirements and...
Nasdaq GlobeNewswire
03/11/2025

Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD)…

This football season, Teva is increasing education around tardive dyskinesia (TD) by launching ‘The Other TD’ campaignTD is a chronic movement disorder impacting one in four people who take certain prescription mental health medications. While TD can impact your daily life, it can be treated without interrupting your mental health treatment 1-4 Younger individuals, men, and racial and ethnic minority groups have lower rates of formal diagnoses despite the...
Nasdaq GlobeNewswire
03/11/2025

Biogen to Highlight Scientific Progress in Rare Kidney Disease at American…

Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights into the mechanism of action of felzartamab and advancing the understanding of its disease modifying potentialExhibitor Spotlight to discuss role of CD38 cells across a range of immune-mediated kidney diseasesFelzartamab, an investigational anti-CD38 monoclonal antibody, is a potentially differentiated therapeutic candidate with promise for a broad range of...
Nasdaq GlobeNewswire
03/11/2025
Altri  Comunicati